Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-06-08

Reporting Person: Sullivan Timothy Eugene (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-08	Common Stock	M	39880	$10.03	Acquired	74141	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-08	Stock Option (Right to Buy)	$10.03	M	39880	Disposed	2027-10-19	Common Stock (39880)	Direct

Footnotes

F1: This option was granted on October 18, 2017 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.